Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience

Francolini, Giulio ; Campi, Riccardo ; et al.

In: Clin Transl Oncol, 2022

academicJournal

PURPOSE: To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab. METHODS/PATIENTS: Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if >5 Gy/fraction were delivered. RESULTS: Ablative RT intent was the only independent predictor of both progression free and overall survival (HR 3.51, 95% CI 1.6–7.5, p = 0.0012 and HR 2.8, 95% CI 0.99–8.07, p = 0.05, respectively). CONCLUSION: Ablative RT may improve oncologic outcomes in selected patients with metastatic RCC treated with Nivolumab as compared to palliative RT.

Titel:	Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience
Autor/in / Beteiligte Person:	Francolini, Giulio ; Campi, Riccardo ; Di Cataldo, Vanessa ; Detti, Beatrice ; Loi, Mauro ; Triggiani, Luca ; La Mattina, Salvatore ; Borghetti, Paolo ; Magrini, Stefano Maria ; Nicosia, Luca ; Alongi, Filippo ; Ghirardelli, Paolo ; Vavassori, Vittorio ; Allegra, Andrea Gaetano ; Aquilano, Michele ; Scoccimarro, Erika ; Peruzzi, Anna ; Pastina, Pierpaolo ; Visani, Luca ; Desideri, Isacco ; Serni, Sergio ; Meattini, Icro ; Livi, Lorenzo
Link:	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418086/ http://www.ncbi.nlm.nih.gov/pubmed/35739349 https://doi.org/10.1007/s12094-022-02844-5
Zeitschrift:	Clin Transl Oncol, 2022
Veröffentlichung:	Springer International Publishing, 2022
Medientyp:	academicJournal
DOI:	10.1007/s12094-022-02844-5
Schlagwort:	Brief Research Article
Sonstiges:	Nachgewiesen in: BASE Sprachen: English Collection: PubMed Central (PMC) Document Type: text Language: English Rights: © The Author(s) 2022, corrected publication 2022 ; https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.